Browse drugs

…ays). During the study period, 30 patients (55.6%) discontinued atogepant. The mean duration until discontinuation was 2.7±1.7 months. Th…

…:CYP2C19–clopidogrel: in poor/intermediate metabolisers, prefer prasugrel or ticagrelor after percutaneous coronary intervention.HLA–B*57…

…ed that RDI is a critical determinant of outcome. Higher RDI of doxorubicin (HR 0.75−0.82) and cyclophosphamide (HR 0.97) was significantly…

…ion strategy. The recent introduction of long-acting injectable cabotegravir (LA-PrEP) has expanded the available options beyond oral therap…

…Background and Importance Daratumumab in combination with lenalidomide-dexamethasone (DR-d) is consid…

…e preventive treatment after lack of efficacy or intolerance to galcanezumab.Material and Methods A retrospective observational study was co…

…ve, single-centre cohort including 46 adult HF patients started Lokelma therapy between January 2023 and September 2025. Demographic, l…

…sure in 10 patients (33.3%).Conclusion and Relevance The use of intranasal esketamine in our hospital generally aligns with the established funding c…

…s. Regarding efficacy, of the subgroup of patients eligible for TYRX (n = 568), one patient among 273 (0.37%) in ‘cohort A’ had an m…

…t antimicrobial resistance and ensure optimal patient outcomes. Co-amoxiclav, a commonly prescribed broad-spectrum antibiotic, is frequently…

…lonal antibody, 23 (41,8%) with galcanezumab and 7 (12,7%) with erenumab.At the end of the follow-up 39 (70,9%) patients had discontinue…

…larger real-world studies are warranted to assess the impact of niraparib in clinical practice.Conflict of Interest No conflict of intere…